parathyroid allotransplant

Parathyroid allotransplant is a **cell therapy** involving the transplantation of parathyroid tissue from a human donor (allogeneic source) to a recipient to restore parathyroid function and treat refractory hypoparathyroidism. The procedure aims for a one-time cure by restoring endogenous parathyroid hormone (PTH) production, circumventing the need for lifelong high-dose calcium and vitamin D supplementation. Various techniques are used, including direct transplantation of donor parathyroid fragments (often 2–3 mm in size), cell culturing, cryopreservation, and encapsulation to reduce immune rejection. Recipients generally require immunosuppression to prevent graft rejection; experimental protocols may use alginate encapsulation or other strategies to limit immune response. The implant site is typically the forearm, chosen for its vascularity and ease of monitoring. The efficacy of parathyroid allotransplant is variable, with a pooled short- to medium-term graft success rate of about 46% with follow-up over 12 months. It is considered for patients with **chronic, treatment-refractory hypoparathyroidism**, particularly those who cannot maintain calcium homeostasis with conventional therapy[3][4][1].

Other names

parathyroid allotransplantationparathyroid gland allotransplantation